Gametocyte Clearance Strategies in Plasmodium Falciparum Infection

Gametocytes are the sexual forms of Plasmodium falciparum that enable transmission from humans to mosquitoes. Unlike asexual blood stages, mature gametocytes sequester in tissues and exhibit reduced sensitivity to most antimalarial drugs. Clearing these stages is essential for interrupting transmission and advancing malaria elimination. Current strategies combine fast-acting artemisinin derivatives with partner compounds that either prevent gametocyte development or sterilise existing gametocytes. Single low-dose primaquine has emerged as a practical adjunct to artemisinin combination therapy, accelerating clearance of mature gametocytes without compromising safety in most settings. Novel transmission-blocking agents such as tafenoquine and methylene blue have shown potent gametocytocidal effects in early trials, offering alternative or complementary approaches. Pharmacokinetic and pharmacodynamic studies inform age- and weight-based dosing regimens, especially in children and populations with high prevalence of glucose-6-phosphate dehydrogenase deficiency. Field trials employing direct mosquito feeding assays confirm that adding a transmission-blocking drug can reduce infectivity to mosquitoes by over 90 per cent within days of treatment. Integrating these insights into treatment guidelines, with appropriate safety monitoring, is critical for reducing the infectious reservoir and curbing malaria spread.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Gametocyte Clearance Strategies in Plasmodium Falciparum Infection publication trend

The graph below shows the total number of articles in gametocyte clearance strategies in plasmodium falciparum infection across all publications each year (not limited to Nature Index journals).

Technical terms

Gametocyte: The sexual stage of Plasmodium falciparum responsible for onward transmission to mosquito vectors.

Gametocytocidal: Describing agents that kill or sterilise gametocytes, preventing development or infectivity.

Artemisinin Combination Therapy (ACT): A first-line regimen pairing an artemisinin derivative with a partner drug to clear asexual parasites and reduce gametocyte carriage.

Transmission-blocking drug: A compound that interrupts the parasite lifecycle by preventing gametocyte infectivity to mosquitoes.

Single low-dose primaquine (SLDPQ): A low, single administration of primaquine (0.25 mg/kg) used alongside ACTs to eliminate mature gametocytes with minimal haemolytic risk.

G6PD deficiency: An inherited enzymatic disorder that increases susceptibility to drug-induced haemolysis, relevant when using 8-aminoquinolines.

References

1. Artemether–lumefantrine with or without single-dose primaquine and sulfadoxine–pyrimethamine plus amodiaquine with or without single-dose tafenoquine to reduce Plasmodium falciparum transmission: a phase 2, single-blind, randomised clinical trial in Ouelessebougou, Mali. The Lancet Microbe (2024).
2. Pharmacokinetics of single low dose primaquine in Ugandan and Congolese children with falciparum malaria. EBioMedicine (2023).
3. Factors affecting haemoglobin dynamics in African children with acute uncomplicated Plasmodium falciparum malaria treated with single low-dose primaquine or placebo. BMC Medicine (2023).
4. Transmission-blocking Effects of Primaquine and Methylene Blue Suggest Plasmodium falciparum Gametocyte Sterilization Rather Than Effects on Sex Ratio. Clinical Infectious Diseases (2019).